Soliton, Inc. SOLY

Cmon $SOLY. Get your head out of your ass!!! Let’s f n go!!

$SOLY hold on now !!! ???

$SOLY break $13 and we’re running!!!

The real fun starts at 5:30! $SOLY

$SOLY CELLULITE TRIAL RESULTS ANY DAY !!! Get in!!!

$SOLY If our news is so bad and our trials are so terrible. Show me one company who can compete with a 6 minute treatment. Non invasive and has an average result of 27% reduction. Did I also mention painless as well..... I’ll wait....

HOUSTON, Oct. 25, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today released interim clinical trial results presented at the American Society for Dermatologic Surgery ("ASDS") Annual Meeting on October 24, 2019.

Soliton announces positive interim clinical trial results with 27% average reduction in scar volume from single
non-invasive treatment. The graph provides a recap of the average for nine scars as one patient was not able to come in for this 6-week timepoint. (PRNewsfoto/Soliton, Inc.)

---

Join our more than 200K fans here to follow the Company: https://soly-investors.com

During our keloid and hypertrophic scar (also known as "fibrotic scars") proof-of-concept trial, we treated 10 people, each of whom received just a single 6-minute treatment with our Rapid Acoustic Pulse ("RAP") device. Before treatment, we photographed each scar with a 3D imaging device that allows for precise measurement of both the volume and height of the raised scar. 6 weeks after that single treatment we took another set of 3D images, which then allowed for an objective comparison of before and after data.

The graph below provides a recap of the average for nine scars as one patient was not able to come in for this 6-week timepoint. There was an average reduction in volume of over 27%, and a reduction in height of almost 17% for the nine patients.

Importantly, there were no treatment-related adverse events of any kind and patients reported little pain from the treatment, so with the primary endpoint of this study being to establish safety and tolerability of RAP for this indication, we believe we are on our way to meeting that endpoint.

"We are very pleased with the interim results from this study," stated Christopher Capelli, MD, founder, President and CEO of Soliton. "We will be conducting an analysis of the 12-week follow-up visit results and providing that data in the coming months. We view this proof-of-concept trial as the starting point for demonstrating that our technology could impact other fibrotic disorders. The same mechanism of action at work to reduce keloid and hypertrophic scars may extend to such indications as capsular contraction, Peyronie's Disease, and even liver fibrosis."

$SOLY 8:00 ????

MIKE: what the hell are you talking about ?!? Friday at 8:00 am. Not 5:00. Get your facts straight !!! Dumbass

4:15-5:15 Chicago Illinois time. I’m EST. Soly Presents in less than an hour!!! $SOLY